Sanofi-Aventis' Menactra Demonstrates Noninferiority To Menomune, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The meningococcal vaccine Menactra met its primary safety endpoint of noninferiority in severe systemic adverse events. Sanofi-Aventis failed to show lot consistency within predefined equivalence limits, FDA says.
You may also be interested in...
Sanofi-Aventis' Menactra Post-Approval Commitments Should Include Long-Term Safety, Efficacy Data
The quadravalent meningococcal conjugate vaccine displayed immunogenicity and safety similar to Menomune, an FDA Advisory Committee says. Sanofi-Aventis says that preliminary results from a three-year follow-up study suggest that Menactra patients have longer antibody persistence than Menomune.
Sanofi-Aventis' Menactra Post-Approval Commitments Should Include Long-Term Safety, Efficacy Data
The quadravalent meningococcal conjugate vaccine displayed immunogenicity and safety similar to Menomune, an FDA Advisory Committee says. Sanofi-Aventis says that preliminary results from a three-year follow-up study suggest that Menactra patients have longer antibody persistence than Menomune.
Aventis/VaxGen AIDS Vaccine Phase III Update Will Be Heard By Advisory Committee Sept. 23
FDA's Vaccines & Related Biologics Advisory Committee will discuss ongoing study of Aventis' ALVAC vCP-1521 HIV vaccine with VaxGen's AIDSVAX. The committee will review Aventis' meningococcal conjugate vaccine Menactra Sept. 22.